AbbVie Ltd Gilead Sciences Ltd and MSD Ltd and sponsored by BristolMyers Squibb None of the sponsors has had any control over the agenda or content Hepatitis C in London practical steps to elimination ID: 531764
Download Presentation The PPT/PDF document "The LJWG 2014 conference is funded throu..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
The LJWG 2014 conference is funded through educational grants from AbbVie Ltd, Gilead Sciences Ltd and MSD Ltdand sponsored by Bristol-Myers Squibb. None of the sponsors has had any control over the agenda or content.Slide2
Hepatitis C in London:practical steps to elimination
Monday 17th
November 2014Guildhall, LondonSlide3
Co-Chairs:Cllr Victoria Borwick
Deputy Mayor of London
Dr Ashley Brown
Consultant
Hepatologist
, St. Mary’s and Hammersmith Hospitals London and Honorary Senior Lecturer, Imperial College London
Hepatitis C in London:
practical steps to eliminationSlide4Slide5
#LJWG2014Slide6
SESSION 1Tools to eliminateSlide7
Dr Helen HarrisClinical Scientist & Research Associate,Public Health England
Tackling Hepatitis
what PHE modelling shows usSlide8
Dee CunniffePolicy Lead & Co-facilitator
London Joint Working Group on Substance Use and Hepatitis C
Data collection
and barriers in the systemSlide9
Professor Sharon HutchinsonProfessor of Epidemiology & Population HealthGlasgow Caledonian University
Health Protection Scotland
How aspirations can be built and levels of performance can be assured:
learning from the Scottish Action PlanSlide10
Mike BurnsCEO & Operations DirectorCAIR Scotland
Needle exchange
impact on hepatitis C pathwaysSlide11
Dr Magdalena HarrisQualitative SociologistLondon School of Hygiene & Tropical Medicine
Supporting people who use drugs and providers:
Hep C info and careSlide12
Claire MunroCo-facilitatorLondon Joint Working Group on Substance Use and Hepatitis C
The role of technology
in supporting patient pathwaysSlide13
Danny MorrisRCGP Clinical LeadHepatitis B & C, Part 1 certificate
RCGP training online:
new training in short bitesSlide14
QUESTIONSDr Ashley BrownConsultant Hepatologist
, St. Mary’s and Hammersmith Hospitals, London and Honorary Senior Lecturer, Imperial College London
Hepatitis C in London:
practical steps to eliminationSlide15
REFRESHMENT BREAK Hepatitis C in London:
practical steps to eliminationSlide16
SESSION 2Collaborate to eliminateSlide17
Dr Éamonn O’Moore
Head of Health & Justice
Health & Wellbeing Directorate
Public Health England
Producing a framework for hepatitis C
through partnership workingSlide18
David BadcockHead of Recovery Engagement
Addaction
The role of drug treatment providers in the care pathway:
practical learning from the South-WestSlide19
Professor Matt HickmanProfessor of Public Health & EpidemiologyUniversity of Bristol
Reducing transmission in PWID
by scaling up drug treatment, OST and needle exchange servicesSlide20
Dr Ashley BrownConsultant Hepatologist, St. Mary’s and Hammersmith Hospitals, London and Honorary Senior Lecturer, Imperial College London
The Updated LJWG ConsensusSlide21
QUESTIONSCllr Victoria Borwick
Deputy Mayor of London
Hepatitis C in London:
practical steps to eliminationSlide22
WORKSHOPSHepatitis C policy development
- East Crypt (adjacent to Livery Hall)
How to reduce blockages in the system by implementing care pathways in collaboration with commissioners
- West Crypt (walk through the East Crypt)
The impact of new drug treatments on elimination
- Livery Hall (main plenary)
Community mobilisation: engaging users to support needle exchanges and peer-led groups
- City Marketing Suite Conference Room (outside
and right)Slide23
LUNCH Hepatitis C in London:
practical steps to eliminationSlide24
The LJWG 2014 conference is funded through educational grants from AbbVie Ltd, Gilead Sciences Ltd and MSD Ltdand sponsored by Bristol-Myers Squibb. None of the sponsors has had any control over the agenda or content.Slide25
Hepatitis C in London:practical steps to elimination
WORKSHOP FEEDBACK
Chair:
Charles Gore
President, World Hepatitis Alliance
Chief Executive, Hepatitis C Trust
Slide26
Dr Suman Verma
Institute of Liver Studies
King's College Hospital London
The impact of new drugs on eliminationSlide27
New Drugs for HCV - key messagesA tornado of new drugs
Combinations of drugs together work best
Less role of interferon8-12 weeks duration
Real life is not as per the trials
Access & affordability
The future is bright but the timelines unclear…Slide28
Chris KellyAssistant Head of Health & Justice CommissioningNHS England
Hepatitis C
policy developmentSlide29
Hepatitis C policy developmentSolutions to policy challenges
Chris Kelly, NHS England
1. Low public and GP awareness –
education programmes, campaigns, training
2
. Policy
deprioritisation
–
overarching policy initiatives
eg
Health Check, Outcomes Framework
3
. Inflexible services/time pressures –
care navigators, community prescribing, digital access to information
4
. Opaque commissioning –
clearer guidance, ensuring strategies in place for longer than duration of tenders, focusing on service delivery and integrationSlide30
Emma BurkeAlcohol & Drugs Programme Manager
Public Health England
How to reduce blockages in the system
by implementing care pathways in collaboration with commissionersSlide31
Reducing blockages in the pathwayBlockages:Lack of understanding commissioning & where the funding comes fromNo recourse to public funds
Treatment too difficult to accessTension between local and national priorities
Short-term planning and commissioningSkills and education all along the pathway (staff and service users, commissioners)
Solutions:
Clarify role of
CCGs
, NHSE & Local Authorities, and funding for new treatments
London-wide Commissioning and pathways
Deliver treatment ‘near the service user’ / in the community / possibly by pharmacist
Need a national driver and long-term plans
Education and formal training
Build Peer-support and user voiceSlide32
Mat SouthwellPartner
Coact
Community mobilisation:
engaging users to support needle exchanges and peer-led groupsSlide33
Community Mobilisation Engaging people who use drugs to support needle exchanges & peer led groups
Mat SouthwellPartner Coact
www.co-act.infoSlide34
Community mobilisation NSPsPeer led NSPsMeaningful participation in traditional
NSPsSecondary needle
exchangeSupplier engagement
matsouthwell@co-act.infoSlide35
Final panelMike Burns
CEO & Operations Director, CAIR Scotland
Jim
Conneely
Hepatitis C Patient and Hepatitis C Trust outreach worker
Professor Graham Foster
Professor of
Hepatology
and Consultant
Hepatologist
, Bart’s and The Royal London Hospitals, London
Professor Matt Hickman
Professor of Public Health and Epidemiology, University of Bristol
Peter Kohn
Director, London Office of Clinical Commissioning Groups
Dr
Éamonn
O’Moore
Head of Health & Justice, Health & Wellbeing Directorate, Public Health England
Dr Sally Porter
Consultant in Addiction Psychiatry, South London and
Maudsley
NHS Foundation Trust, and Turning PointSlide36
The LJWG 2014 conference is funded through educational grants from AbbVie Ltd, Gilead Sciences Ltd and MSD Ltdand sponsored by Bristol-Myers Squibb. None of the sponsors has had any control over the agenda or content.